Anti-Viral Therapies Market to Reach $46.21 Bn, Globally, by 2026 at 2.4% CAGR: Allied Market Research

PORTLAND, Oregon, June 2, 2020 /PRNewswire/ -- Allied Market Research published a report, titled, "Anti-viral Therapies Market by Type (Generic Drugs and Branded Drugs), Application (HIV, Hepatitis, Herpes Virus, Influenza, and Other Applications), and Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026."According to the report, the global anti-viral therapies market garnered $38.31 billion in 2018, and is estimated to reach $46.21 billion by 2026, registering a CAGR of 2.4% from 2019 to 2026.

Drivers, restraints, and opportunities

Increase in problem of viral infection and stronger pipeline of anti-viral drugs across the globe drive the growth of the global anti-viral therapies market. However, high cost of anti-viral therapies hinders the market growth. On the other hand, rise in number of product approvals for combination therapy create new opportunities in the coming years.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/6643

COVID-19 Scenario

• The coronavirus outbreak has not much affected the global anti-viral therapies market. In addition, the anti-viral therapies also include essential treatments on HIV, hepatitis and herpes, which drive the demand in the market.
• Moreover, due to the rise in awareness regarding common symptoms of coronavirus, the market has observed increased use of anti-viral therapies, which may aid the industry in terms of revenue

The branded drugs segment to maintain its lead status in terms of revenue throughout the forecast period

Based on type, the branded drugs segment accounted for more than half of the global anti-viral therapiesmarket in 2018, and is expected to maintain its lead status in terms of revenue throughout the forecast period. This is due toavailability of large number of branded drugs for treating various viral infections.However, the generic drugssegment is estimated toportray the highest CAGR of 2.5% from 2019 to 2026, owing toincrease in number of branded drugs losing their patents

The nucleotide polymerase inhibitor segment to maintain its leadership position during the forecast period

Based on mechanism of action, the nucleotide polymerase inhibitor segment contributed to the highest market share with nearly two-fifth of the global anti-viral therapies market in 2018, and is estimated to maintain its leadership position during the forecast period. This is attributed toits increasing usage in Hepatitis C infection and is considered to be the first-line treatment for any viral infection. However, the reverse transcriptase inhibitors segment is estimated to generate the fastest CAGR of 3.1% from 2019 to 2026. This is attributed toincrease in FDA approvals for treating viral infection by reverse transcriptase inhibitor mechanism.

North America to maintain its dominant by 2026

Based on region, North Americaaccounted for the highest share based on revenue, holding for more than one-thirdof the global anti-viral therapies market in 2018, and is projected to maintain its dominant position throughout the forecast period. This is attributed to rise in incidences of infectious diseases across the region.However, Asia-Pacific is estimated toportray the fastest CAGR of 2.8% from 2019 to 2026, owing togrowing population base infected with infectious diseases in the region, presence of several generic pharmaceutical players, and increase in investment for drug development in South Asian countries.

For Purchase Enquiry at:  https://www.alliedmarketresearch.com/purchase-enquiry/6643

Leading market players

• F. Hoffmann-La Roche Ltd.
• Gilead Sciences
• GlaxoSmithKline
• Bristol-Myers-Squibb
• Abbott Laboratories
• AstraZeneca plc
• AbbVie Inc.
• AurobindoPharma Limited
• Johnson & Johnson
• Merck & Co., Inc.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter

Get more information: https://www.alliedmarketresearch.com/library-access

Similar Reports:

Gene Therapy Market - Global Opportunity Analysis and Industry Forecast, 2019–2026

Lung Cancer Therapeutic Market - Global Opportunity Analysis and Industry Forecast, 2020-2027

Bio-implants Market - Global Opportunity Analysis and Industry Forecast, 2019–2026

Oncology/Cancer Drugs Market - Global Opportunity Analysis and Industry Forecast, 2019–2026

Cardiac Biomarkers Market - Global Opportunity Analysis and Industry Forecast, 2019–2026

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
[email protected]
Web: https://www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research 

View original content:http://www.prnewswire.com/news-releases/anti-viral-therapies-market-to-reach-46-21-bn-globally-by-2026-at-2-4-cagr-allied-market-research-301069274.html

SOURCE Allied Market Research